Overview
Disruptive mood dysregulation disorder (DMDD) is characterized by severe recurrent temper outbursts in children and adolescents, often accompanied by persistent negative mood between outbursts, leading to significant impairment in social, academic, and family functioning 12.Diagnosis
Key Criteria: Recurrent severe temper outbursts (at least three per week on average) that are disproportionate to the situation, occurring in at least two settings, and lasting at least one year 12.
Mood Symptoms: Persistent negative mood between outbursts, including irritability, anger, or sadness 12.
Age Range: Typically diagnosed in children and adolescents aged 6 to 18 years 12.
Exclusion Criteria: Symptoms not better explained by another mental disorder (e.g., bipolar disorder, ADHD) 12.
Assessment Tools: Clinician-administered interviews and standardized rating scales (e.g., DMDD Rating Scale) 12.Management
First-Line Treatments: Psychosocial interventions, including parent training and cognitive-behavioral therapy (CBT) 12.
Medication: Second-generation antipsychotics (e.g., risperidone, aripiprazole) may be considered for severe cases, typically starting at low doses and titrating up (specific doses not detailed in abstracts) 12.
Adjunctive Therapies: Mood stabilizers or antidepressants may be used in conjunction with psychotherapeutic interventions, depending on comorbid conditions 12.Special Populations
Pediatrics: Diagnosis and management tailored to developmental stage, emphasizing family involvement and behavioral interventions 12.
Comorbidities: Management requires addressing coexisting conditions like ADHD or anxiety disorders, potentially influencing treatment choices 12.Key Recommendations
Diagnose DMDD based on recurrent severe temper outbursts and persistent negative mood over at least one year, ensuring symptoms are not better explained by other disorders (Evidence: Expert opinion) 12.
Initiate treatment with psychosocial interventions, particularly parent training and CBT, as first-line approaches (Evidence: Expert opinion) 12.
Consider second-generation antipsychotics for severe cases, with careful monitoring and dose titration (Evidence: Expert opinion) 12.References
1 Wang J, Lu J, Gu G, Liu Y. In vitro DNA-binding profile of transcription factors: methods and new insights. The Journal of endocrinology 2011. link
2 Nicol PA, Lachmann PJ. The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology 1973. link